DHR Health Institute for Research and Development Recognized as a “Top Performing Site” Once Again

Translate to Spanish or other 102 languages!

THREE-PEAT TEAM: The DHR Health Institute for Research and Development pictured here has been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This is the third consecutive time the Institute has received this prestigious recognition. Courtesy image
THREE-PEAT TEAM: The DHR Health Institute for Research and Development pictured here has been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This is the third consecutive time the Institute has received this prestigious recognition. Courtesy image
- Advertisement -

EDINBURG, Texas – The DHR Health Institute for Research and Development is delighted to announce that it has once again been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This marks the third consecutive time the Institute has received this prestigious distinction.

This recognition highlights the ongoing excellence and impact of the Research Institute as it continues to advance cancer research and improve patient outcomes.

“We are deeply honored and this recognition would not be possible without the assistance of the DHR Health Oncology Institute and the leadership of Dr. Jose Cruz,” said Dr. Scott Lillibridge, executive vice president for the DHR Health Institute for Research and Development.

- Advertisement -

SWOG is a global cancer research community supported by the National Cancer Institute (NCI), and recognition as a “Top Performing Site” signifies exceptional performance in clinical trial enrollment, data quality, and patient care standards.

The DHR Health Institute for Research and Development remains committed to innovation and delivering high-quality research opportunities to all residents of the Rio Grande Valley. They are located at 5323 S. McColl Road in Edinburg. For more information about clinical trials in the areas of liver, obesity, cancer, neurology, oncology and urology, call the Institute at (956) 362-2390.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Robotic Surgery Program Expanded at STHS McAllen

From smaller incisions and less pain to shorter hospital stays and faster recovery times, robotic-assisted surgery is changing the way patients experience surgical care.

Texas Oncology to Host Breast Cancer Awareness Symposium in McAllen. FULL TO CAPACITY. NO MORE ROOM.

The Breast Cancer Awareness Symposium 2026 is an educational and networking event hosted by Texas Oncology and sponsored by Caris Life Sciences, bringing together oncology specialists, surgeons, advanced practice providers, and community healthcare professionals to discuss the latest advances in breast cancer prevention, diagnosis, treatment, survivorship, and reconstruction. The symposium's theme, "Breast Cancer 2026: Early Detection, Modern Care, and Survivorship Through Community Partnership," highlights the importance of multidisciplinary collaboration and patient-centered care

Highway Crash Leads to Unexpected STC Connection

What began as a flat tire on the side of a highway turned into a frightening collision and an unexpected encounter for South Texas College faculty member Jesus Amaya, when the paramedic who responded to the scene turned out to be one of STC’s graduates.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
- Advertisement -